For the Inventor, By the Inventor

Enter assignee name

Ono Pharmaceutical Co., Ltd.

USPTO Granted Patents = 575

CIPO Patents = 14

EPO Patents = 133

Trademarks = 8

Forward Citations = 6,352

Loading Chart...

Loading Chart...

586 inventors (with patents filed for the assignee):

Shiro Shibayama (49 out of 52 patents)

Masaki Hayashi (43 out of 46 patents)

Yoshinobu Arai (40 out of 41 patents)

4. Shuichi Ohuchida (40 out of 43 patents)

5. Hiroyuki Ohno (31 out of 35 patents)

6. Kousuke Tani (30 out of 33 patents)

7. Nobuyuki Hamanaka (30 out of 30 patents)

8. Tasuku Honjo (27 out of 40 patents)

9. Masaaki Toda (27 out of 29 patents)

10. Kaoru Kobayashi (24 out of 40 patents)

11. Hisao Nakai (24 out of 25 patents)

12. Katsuhiro Imaki (23 out of 23 patents)

13. Kazuyuki Ohmoto (22 out of 27 patents)

14. Jun Takeuchi (21 out of 23 patents)

15. Yoshikazu Takaoka (21 out of 23 patents)

Core Competencies:

S1P5 Receptor Agonists

Immune Checkpoint Inhibitors

Bispecific Antibodies

KDM5 Inhibitors

Cancer Biomarkers

Chimeric Antigen Receptors

Combination Therapy

STING Agonists

HER2 Targeting Agents

TREK Channel Activators

ABHD6 Antagonists

Purinone Derivatives

575 patents: Sort by Forward Citations

1. 12497377 - Tricyclic spiro compound (2025-12-16),

2. 12459890 - Salt and crystal form of compound having agonistic activity to S1P5 receptor (2025-11-04),

3. 12447150 - Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy (2025-10-21),

4. 12325746 - Bispecific antibody (2025-06-10),

5. 12269817 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof (2025-04-08),

6. 12258308 - Benzene derivative (2025-03-25),

7. 12240903 - Biomarkers for determining the effectiveness of immune checkpoint inhibitors (2025-03-04),

8. 12234289 - Immunosuppresive agent (2025-02-25),

9. 12201603 - Bicyclic compound and use thereof for medical purposes (2025-01-21),

10. 12186392 - Combination therapy of an anti CD20 antibody with a BTK inhibitor (2025-01-07),

11. 12152049 - STING agonistic compound (2024-11-26),

12. 12122846 - Chimeric antigen receptor for tumor targeting (2024-10-22),

13. 12091461 - Bispecific antibody (2024-09-17),

14. 12049445 - Compounds having S1P5 receptor agonistic activity (2024-07-30),

15. 12036204 - Pharmaceutical composition for treating tumor (2024-07-16),

ONO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company focuses on the research, development, manufacture, and sale of pharmaceutical products. It offers prescription pharmaceuticals, over-the-counter drugs, and diagnostic reagents. ONO PHARMACEUTICAL CO., LTD. operates both domestically and internationally, providing medical solutions in various therapeutic areas including oncology, immunology, and neurology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

575 Patents

#40 in Osaka

#333 in Japan

#1,642 in the World

Ono Pharmaceutical Co., Ltd.

Forward Citations = 6,352

586 inventors:

Shiro Shibayama (49 out of 52 patents)

Masaki Hayashi (43 out of 46 patents)

Yoshinobu Arai (40 out of 41 patents)

4. Shuichi Ohuchida (40 out of 43 patents)

5. Hiroyuki Ohno (31 out of 35 patents)

Please report any incorrect information to support@idiyas.com

Loading…